LSV Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

LSV Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-103,100	Closed	-$3.31M	–	1031
2017 Q1	$3.31M	Hold	103,100	–	–	0.01%	635
2016 Q4	$3.74M	Buy	103,100 +2,300	+2%	+$91.8K	0.01%	611
2016 Q3	$4.64M	Hold	100,800	–	–	0.01%	551
2016 Q2	$5.06M	Hold	100,800	–	–	0.01%	527
2016 Q1	$5.39M	Sell	100,800 -15,745	-14%	-$924K	0.01%	500
2015 Q4	$7.65M	Buy	116,545 +29,445	+34%	+$1.82M	0.02%	440
2015 Q3	$4.92M	Buy	87,100 +14,400	+20%	+$934K	0.01%	495
2015 Q2	$4.3M	Hold	72,700	–	–	0.01%	509
2015 Q1	$4.53M	Hold	72,700	–	–	0.01%	493
2014 Q4	$4.18M	Buy	72,700 +3,300	+5%	+$184K	0.01%	495
2014 Q3	$3.73M	Buy	69,400 +31,300	+82%	+$1.66M	0.01%	504
2014 Q2	$2M	Buy	+38,100	New	+$1.95M	﹤0.01%	593

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

LSV Asset Management's TEVA Position: Q2 2017 in Review

LSV Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2017, closing a stake of 103,100 shares — an estimated $3.31M sold.

LSV Asset Management first reported a position in TEVA in Q2 2014 and held it in 12 quarters. The position peaked at $7.65M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

LSV Asset Management reported no remaining Teva Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
LSV Asset Management sold 103,100 Teva Pharmaceuticals shares in Q2 2017, an estimated $3.31M.
LSV Asset Management first reported a position in Teva Pharmaceuticals in Q2 2014 and held it in 12 quarters.
LSV Asset Management's Teva Pharmaceuticals position peaked at $7.65M in Q4 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on LSV Asset Management's 13F filing for Q2 2017, filed 9 Aug 2017.